Published in Drug Discov Today on July 11, 2008
ThANKs for the repeat: Intracellular pathogens exploit a common eukaryotic domain. Cell Logist (2011) 1.06
Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther (2011) 1.04
Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther (2012) 0.92
Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors. PLoS Pathog (2012) 0.88
5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland. MAbs (2011) 0.87
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis (2012) 0.86
High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain. PLoS One (2012) 0.82
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther Deliv (2011) 0.82
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. MAbs (2013) 0.82
Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein. Retrovirology (2012) 0.82
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine (2015) 0.82
Single molecule fluorescence detection and tracking in mammalian cells: the state-of-the-art and future perspectives. Int J Mol Sci (2012) 0.82
Anti-ids in allergy: timeliness of a classic concept. World Allergy Organ J (2010) 0.81
Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep (2015) 0.80
Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species. Appl Environ Microbiol (2015) 0.80
Peptide aptamers: development and applications. Curr Top Med Chem (2015) 0.80
Engineered IgG1-Fc - one fragment to bind them all. Immunol Rev (2016) 0.80
Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library. J Biol Chem (2016) 0.80
Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease. J Biol Chem (2014) 0.79
Computational design of binding proteins to EGFR domain II. PLoS One (2014) 0.79
Computational tools for epitope vaccine design and evaluation. Curr Opin Virol (2015) 0.79
Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing. J Biol Chem (2014) 0.79
NextGen protein design. Biochem Soc Trans (2013) 0.78
Bioengineering of bacteria to assemble custom-made polyester affinity resins. Appl Environ Microbiol (2014) 0.78
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother Radiopharm (2010) 0.77
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J Immunother Cancer (2015) 0.76
Effective molarity redux: Proximity as a guiding force in chemistry and biology. Isr J Chem (2013) 0.76
AnkPlex: algorithmic structure for refinement of near-native ankyrin-protein docking. BMC Bioinformatics (2017) 0.75
Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Sci Rep (2014) 0.75
Monobodies and other synthetic binding proteins for expanding protein science. Protein Sci (2017) 0.75
A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int J Mol Sci (2017) 0.75
Intellectual property issues of immune checkpoint inhibitors. MAbs (2015) 0.75
Identification and characterization of a novel Sso7d scaffold-based binder against Notch1. Sci Rep (2017) 0.75
Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget (2017) 0.75
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol (2004) 3.34
Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol (2007) 2.89
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol (2003) 2.81
Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad Sci U S A (2003) 1.98
Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure (2007) 1.93
Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. Structure (2005) 1.75
Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods (2007) 1.68
Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol (2007) 1.67
Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res (2010) 1.51
Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem (2004) 1.46
Designing repeat proteins: modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. J Mol Biol (2003) 1.39
Folding of a designed simple ankyrin repeat protein. Protein Sci (2004) 1.20
Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J Biol Chem (2005) 1.17
A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett (2003) 1.15
DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel (2007) 1.13
Consensus design of repeat proteins. Chembiochem (2004) 0.98
Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin. Acta Crystallogr D Biol Crystallogr (2008) 0.97
DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol (2009) 0.96
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog (2008) 0.95
Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J Biol Chem (2006) 0.95
DARPins against a functional IgE epitope. Immunol Lett (2010) 0.93
Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Eng Des Sel (2006) 0.89
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis (2012) 0.86
Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites. Mol Cell Biol (2012) 0.85
Molecular dynamics study of the stabilities of consensus designed ankyrin repeat proteins. Proteins (2006) 0.82
Designed ankyrin repeat proteins as anti-idiotypic-binding molecules. Ann N Y Acad Sci (2007) 0.81